Geneva, Switzerland, September 24, 2021, 8:00am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis, announces today that it has entered into a research agreement with Northwestern University to further investigate the relationship between HERV-W ENV (W-ENV) and long-COVID neuropsychiatric syndromes.
https://geneuro.ch/data/news/2021.09.24-GN-PR-NW-agreement-ENG.pdf